Fluvoxamine

Indications & formulation #

Obsessive–compulsive disorder in adults; extended-release formulation. This reference covers the selected formulation; other indications and products need their own evidence.

Dose reference #

Adult educational reference · Oral extended-release capsule · United States. The clinician selects treatment after assessment; this page does not calculate or change a prescription.

Start 100 mg at bedtime; increments of 50 mg at weekly intervals as tolerated, maximum 300 mg/day. Do not crush or chew.

Contraindications & important cautions #

Avoid MAOIs, tizanidine, thioridazine, pimozide, alosetron and ramelteon. Metabolic interactions require full medication reconciliation.

Selected important cautions; consult the full product information for all contraindications and warnings.

Adverse effects #

Gastrointestinal effects, sedation or activation and SSRI class cautions require assessment.

Interactions #

Important metabolic inhibition includes CYP1A2 and CYP2C19; review clozapine, caffeine and other relevant substrates individually.

Monitoring #

Medication reconciliation is central. Review symptoms, adverse effects and exposure changes after adding or removing interacting agents.

Special populations #

Use slower titration in older adults and hepatic impairment. This ER starting schedule is not the immediate-release schedule.

Adult scope. Pregnancy, breastfeeding and pediatric use require the exact product’s population-specific guidance and individual assessment.

Discontinuation, restarting & counseling #

Reduce gradually and reassess OCD symptoms, withdrawal and interacting medicines.

Brands & products #

Reference coverage #

Structured summary of selected adult uses, not an exhaustive monograph. Indian product authorization and local prescribing requirements have not been reconciled.